ASH 2023: MRD Highlights in BioPharma Drug Development

Read More

Browse our 650+ Publications​

Latest Publications

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Niemann C, et al.
Lancet Oncology
November 2023
Authors and Affiliates
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P Kater

Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.

Izutsu K, et al.
Cancer Science
November 2023
Authors and Affiliates
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Minh Dinh, David Soong, Hidehisa Noguchi, Jeppe Klint Buchbjerg, Elena Favaro, Noriko Fukuhara

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.

Minson A, et al.
Blood
October 2023
Authors and Affiliates
Adrian G Minson, Nada Hamad, Chan Y Cheah, Constantine S Tam, Piers Blombery, David A Westerman, David S Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F Seymour, Molly Robertson, Imogen Caldwell, Georgina Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel M Koldej, Michael Dickinson Citation

Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes from a Single-Center Study

Ashouri K, et al.
Clinical Lymphoma Myeloma & Leukemia
October 2023
Authors and Affiliates
Karam Ashouri, Vinay Nittur, Anush A. Ginosyan, Jennifer Hwang, Blake Adnani, Denaly Chen, Lakshmi Sav itala-Damerla, Kimberly Schiff, Preet Chaudhary, Alexandra E. Kovach, Abdullah Ladha, Imran Siddiqi, Amir Ali, Karrune Woan, Eric Tam, George Yaghmour

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.

Bahlis, N, et al.
Nature Medicine
October 2023
Authors and Affiliates
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P Chu, Andrew Dalovisio, Michael Sebag, Alexander M Lesokhin

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

Costa L, et al.
Lancet Haematology
September 2023
Authors and Affiliates
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt, Kelly N Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D'Souza, Aric C Hall, Pamela Hardwick, James Omel, Robert F Cornell, Parameswaran Hari, Natalie S Callander

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.

Kubicki T, et al.
British Journal of Haematology
September 2023
Authors and Affiliates
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Jan Maciej Zaucha, Damian Mikulski, Olga Czabak, Oscar B Lahoud, Andrew Stefka, Benjamin A Derman, Andrzej J Jakubowiak.

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Epstein-Peterson ZD, et al.
Haematologica
August 2023
Authors and Affiliates
Zachary D. Epstein-Peterson1 , Esther Drill2 , Umut Aypar3 , Connie Lee Batlevi1 , Philip Caron1 , Ahmet Dogan3 , Pamela Drullinsky1 , John Gerecitano1 , Paul A. Hamlin1 , Caleb Ho3 , Allison Jacob4 , Ashlee Joseph1 , Leana Laraque1 , Matthew J. Matasar1 , Alison J. Moskowitz1 , Craig H. Moskowitz1 , Chelsea Mullins4 , Colette Owens1 , Gilles Salles1 , Heiko Schöder5 , David J. Straus1 , Anas Younes1 , Andrew D. Zelenetz1 , and Anita Kumar1 1 Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center 2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center 3Department of Pathology, Memorial Sloan Kettering Cancer Center 4Adaptive Biotechnologies, Seattle, WA, USA 5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

The overlap of skin and blood T-cell clones in early-stage mycosis fungoides.

Joffe D, et al.
Blood Advances
August 2023
Authors and Affiliates
Daniel Joffe BS1, Safiyyah Bhatti MD1,2, Lauren Banner BS1, Romsin Zaya BS1, Laura Gleason BS1, Anjali Mishra PhD2, Ilan Kirsch MD3, Pierluigi Porcu MD2, Neda Nikbakht MD, PhD1 1 - Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA 2 - Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 3 - Adaptive Biotechnologies, Seattle, WA